Elanco Animal Health (ELAN) vs TG Therapeutics (TGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
TG Therapeutics (TGTX) has outperformed Elanco Animal Health (ELAN) over the past year, gaining 98.2% versus a gain of 15.7%. Over five years, TGTX leads with a +164.1% price change compared with -14.8% for ELAN. Elanco Animal Health is the larger company by market cap ($12.87 billion vs $9.57 billion), about 1.3 times the size, while TG Therapeutics is growing revenue faster (+87.3% vs +6.2%).
On valuation, Elanco Animal Health trades at a lower forward P/E (19.9x vs 24.8x for TG Therapeutics). TG Therapeutics converts more of its revenue into profit, with a net margin of 72.6% versus -4.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELAN | TGTX |
|---|---|---|
| Share price | $25.74 | $63.34 |
| Market cap | $12.87B | $9.57B |
| 1-day change | -2.09% | -2.37% |
| YTD return | +13.74% | +112.48% |
| 1-year return | +15.69% | +98.25% |
| 5-year return | -14.82% | +164.14% |
| P/E ratio (TTM) | — | 94.54 |
| Forward P/E | 19.91 | 24.81 |
| EPS (TTM) | $-0.30 | $0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.71B | $616.29M |
| Revenue growth (YoY) | +6.22% | +87.32% |
| Net income (latest FY) | $-232.00M | $447.18M |
| Gross margin | 54.99% | 83.66% |
| Operating margin | — | 20.01% |
| Net margin | -4.92% | 72.56% |
| 52-week high | $27.98 | $68.03 |
| 52-week low | $19.40 | $26.76 |
| Distance from 52-week high | -8.01% | -6.89% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +20.44% | +9.61% |
| Average volume | 5.32M | 1.86M |
| Shares outstanding | 499.83M | 151.15M |
| Employees | 9,400 | 399 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TGTX has outperformed ELAN by 82.6 percentage points over the past year.
- TG Therapeutics is more profitable, keeping 72.6 cents of every revenue dollar as net income versus -4.9 cents for Elanco Animal Health.
- TG Therapeutics grew revenue faster in its latest fiscal year (+87.32% vs +6.22%).
About Elanco Animal Health
ELAN stock →Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark.
Health Care · Biotechnology: Pharmaceutical Preparations · 9,400 employees
About TG Therapeutics
TGTX stock →TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 399 employees
ELAN vs TGTX FAQ
Which is bigger, Elanco Animal Health or TG Therapeutics?
Elanco Animal Health (ELAN) is larger, with a market capitalization of $12.87B compared with $9.57B for TG Therapeutics (TGTX).
Which stock has performed better over the past year, ELAN or TGTX?
TGTX returned +98.25% over the past 12 months, compared with +15.69% for ELAN (price return, excluding dividends). Past performance does not predict future results.
Are Elanco Animal Health and TG Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.